(Nanowerk Spotlight) The human digestive system presents a formidable challenge for medication delivery. Powerful stomach acids, protective barriers, and complex immune responses make it difficult for therapeutic compounds to reach their intended targets. This challenge is particularly acute in inflammatory bowel disease (IBD), where inflammation creates additional obstacles for treatment. Medications must navigate through multiple defensive layers while maintaining their therapeutic properties – similar to delivering a fragile package through a obstacle course.
Conventional oral medications often fail to reach inflamed intestinal tissues in sufficient concentrations. The stomach’s acidic environment can destroy drugs before they reach the intestines. Even if medications survive this acid bath, they face another barrier: a thick protective layer of mucus and tightly packed cells that shield the intestinal wall. In IBD patients, this challenge is compounded by elevated levels of reactive oxygen species – unstable molecules that damage healthy tissue and create a hostile environment for healing.
Traditional approaches rely on protective coatings that dissolve in the intestines, but these passive systems cannot actively seek out inflamed areas or penetrate tissue effectively. More sophisticated delivery methods using basic nanoparticles have shown promise, but they still drift randomly rather than moving purposefully to their targets. The ideal solution would combine protection, precise targeting, and the ability to actively move through intestinal tissue.
Researchers at Tianjin University have developed exactly such a system, creating self-propelling particles that actively navigate to inflamed areas while carrying anti-inflammatory medication. Think of these particles as microscopic submarines that use the body’s own inflammatory response as their fuel.
At the heart of their system is a nanoparticle of about 90 nm. This “nanomotor” combines three key components: a gold core for stability, a porous outer layer that holds medication (like tiny sponges soaking up water), and a special coating that converts harmful inflammatory molecules into oxygen bubbles. These bubbles don’t just reduce inflammation – they propel the nanoparticle forward, pushing it deeper into affected tissue.
The researchers loaded these particles with astaxanthin, a natural anti-inflammatory compound found in certain marine organisms. To protect this cargo during its journey through the stomach, they encased the particles in protective capsules created using 3D printing technology. These capsules have an outer shell that remains intact in stomach acid but dissolves in the different chemical environment of the intestines, like a time-release package.
Schematic illustration of the fabrication process of Astaxanthin nanomotor microcapsules (AST@NMs@MCs) and anti-inflammatory therapy for Dextran Sulfate Sodium (DSS)-induced IBD.
Laboratory testing showed that these particles effectively shield healthy cells from inflammatory damage while encouraging immune cells to switch from an inflammatory state to a healing one. When tested in mice with IBD, the treatment reduced intestinal inflammation and helped repair damaged tissue barriers. Importantly, it also helped restore balance to the community of beneficial bacteria in the gut that typically becomes disrupted in IBD patients.
The system’s success lies in its ability to address multiple aspects of IBD simultaneously. The particles convert harmful molecules into propulsion power, allowing them to actively move through tissue rather than drifting randomly. As they move, they deliver medication precisely where needed while also helping to restore the natural bacterial balance that maintains gut health.
This approach represents a significant advance in drug delivery technology. By combining protection, precise targeting, and self-propulsion, these particles overcome many traditional barriers to effective IBD treatment. The work also provides a template for developing similar systems for other conditions that require precise drug delivery to specific locations in the body.
While additional research will be needed to evaluate this system in humans, the underlying principles demonstrate how merging different technologies can create more effective treatments for complex diseases. The ability to convert harmful molecules into a means of propulsion, while simultaneously delivering therapeutic compounds, points toward a new generation of smart drug delivery systems that work in harmony with the body’s own processes.
Get our Nanotechnology Spotlight updates to your inbox!
Thank you!
You have successfully joined our subscriber list.
Become a Spotlight guest author! Join our large and growing group of guest contributors. Have you just published a scientific paper or have other exciting developments to share with the nanotechnology community? Here is how to publish on nanowerk.com.
